This article was previously published August 1, 2019, and has been updated with new information. According to statistics for 2019,1 14% of Americans aged 71 or older have some form of dementia. Alzheimer’s disease, which is the most severe and lethal form of dementia, affects an estimated 5.8 million Americans. Of those, 81% are over… Read More »
The U.S. Food and Drug Administration granted fast track designation to UB-311, a vaccine for Alzheimer’s disease made by biotechnology company Vaxxinity.1 The shot is an anti-amyloid beta immunotherapeutic vaccine that reportedly treats Alzheimer’s disease by targeting aggregated amyloid beta in the brain.2 Aside from the potential problems that can arise when a vaccine is… Read More »
Maybe you occasionally forget appointments or social events, or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making a decision. According to a online symptoms quiz from Biogen and Japanese partner Eisai, those are just a handful of signs of mild cognitive impairment (MCI), an early indication of… Read More »
Advertisement Continue reading the main story Supported by Continue reading the main story How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were… Read More »
How do you sell an Alzheimer’s treatment mired in controversy over its disputed benefits? Biogen is turning to “Jim and Jane” for help. That’s the couple grappling with the memory-robbing disease that Biogen and Japanese partner Eisai have placed at the center of their new marketing campaign, “It’s Time We Know.” The campaign is designed… Read More »
Medicare might restrict patient access to Alzheimer’s treatment priced at $ 56,000 for a year’s supply to soften the financial blow to the federal insurance program’s budget. “Whether or not that drug will be covered by Medicare and Medicaid is is an outstanding question, something that HHS will have to deal with,” said Health and… Read More »